ANNOVERA (segesterone acetate and ethinyl estradiol) by Mayne Pharma is estrogen receptor agonists [moa]. Approved for pregnancy. First approved in 2018.
Drug data last refreshed 12h ago · AI intelligence enriched 1mo ago
ANNOVERA is a combined hormonal contraceptive ring containing segesterone acetate and ethinyl estradiol, designed to prevent pregnancy through estrogen receptor agonism. Administered vaginally, it provides a non-daily contraceptive option with a 3-week on/1-week off cycle. The product works by suppressing ovulation and altering cervical mucus to inhibit sperm penetration.
Product is at peak commercial phase with modest Part D uptake; team likely focused on market penetration and maintaining share against established competitors.
Estrogen Receptor Agonists
Estrogen
ANNOVERA offers career opportunities in a niche but stable contraceptive market with a peak-stage product supported by strong patent protection through 2039. Roles focus on competitive positioning against NUVARING, market penetration in women's health, and navigating payer/formulary dynamics in contraception.
Worked on ANNOVERA at Mayne Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo